Related Experiment Video

Updated: Apr 17, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Effectiveness of regular versus glargine insulin in stable critical care patients receiving parenteral nutrition: a

Mohammad Bagher Oghazian1, Mohammad Reza Javadi, Mania Radfar

  • 1Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Pharmacotherapy
|February 18, 2015
PubMed

Insights

Glargine insulin and regular insulin provide similar glycemic control in critical care patients receiving parenteral nutrition. Both regimens demonstrated comparable rates of hyperglycemia and hypoglycemia, indicating comparable safety and effectiveness.

Area of Science:

  • Critical care medicine
  • Endocrinology
  • Pharmacology

Background:

  • Parenteral nutrition (PN) is essential for critically ill patients.
  • Maintaining optimal glycemic control is crucial for patient outcomes in the intensive care unit (ICU).
  • Different insulin regimens are used to manage blood glucose levels during PN.

Purpose of the Study:

  • To compare the effectiveness and safety of glargine insulin versus regular insulin for glycemic control in stable critical care patients receiving PN.
  • To evaluate blood glucose levels, hyperglycemia, and hypoglycemia rates between the two insulin regimens.

Main Methods:

  • Prospective, randomized open-label clinical trial involving stable postoperative critical care patients.
  • Patients received PN with regular insulin, followed by randomization to either continued regular insulin or glargine insulin for 3 days.
  • Blood glucose levels were monitored every 6 hours.

Main Results:

  • No significant differences in mean daily dextrose or insulin doses between the groups.
  • Similar percentages of blood glucose values within the target range (110-180 mg/dl), hyperglycemia (>180 mg/dl), and hypoglycemia (<70 mg/dl).
  • Mean daily blood glucose levels were not significantly different between the regular insulin and glargine insulin groups.

Conclusions:

  • Glargine insulin, when added to PN, offers similar glycemic control compared to regular insulin in stable critical care patients.
  • The rates of hyperglycemia and hypoglycemia were comparable between the two insulin regimens.
  • These findings suggest glargine insulin is a viable alternative for glycemic management in this patient population.
Abstract

Keywords:
glargine insulinglycemic controlparenteral nutritionregular insulin

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.5K
A Model of Chronic Nutrient Infusion in the Rat08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

13.2K

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Parentral Nutrition: Centeral and Peripheral Parental Nutrition01:27

Parentral Nutrition: Centeral and Peripheral Parental Nutrition

Parenteral Nutrition (PN) delivers essential nutrients directly into the bloodstream, bypassing the digestive system. It is commonly used for individuals with severe digestive disorders or conditions that prevent normal nutrient absorption.
PN can be administered through two primary routes:
1. Central Parenteral Nutrition (CPN):
CPN involves delivering a high concentration of nutrients through a large vein. This is typically achieved using a Peripherally Inserted Central Catheter (PICC) or,...
1.8K
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding01:15

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
1.8K
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
1.2K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.4K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
995